UPDATE: Jefferies Upgrades Sequenom to Buy on Reimbursement Coverage Outlook

Jefferies raised its rating on Sequenom SQNM from Hold to Buy with a reiterated $7 price target. Jefferies said, "We are upgrading shares of SQNM to Buy (from Hold) based on results from a proprietary survey we conducted of US commercial payors representing some 44 million lives, which indicated SQNM is experiencing meaningful traction obtaining reimbursement coverage for its T21 LDT test at average rates that we find more than acceptable. Our $7 price target (>90% upside) is unchanged." Sequenom closed at $3.60 on Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorUpgradesPrice TargetPre-Market OutlookAnalyst RatingsJefferies
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!